330 related articles for article (PubMed ID: 17222883)
21. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
[TBL] [Abstract][Full Text] [Related]
22. Immunological analyses of human papillomavirus capsids.
Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
[TBL] [Abstract][Full Text] [Related]
23. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
24. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
25. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
26. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP
BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660
[TBL] [Abstract][Full Text] [Related]
27. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1.
McClements WL; Wang XM; Ling JC; Skulsky DM; Christensen ND; Jansen KU; Ludmerer SW
Virology; 2001 Oct; 289(2):262-8. PubMed ID: 11689049
[TBL] [Abstract][Full Text] [Related]
28. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.
Fleury MJ; Touzé A; Alvarez E; Carpentier G; Clavel C; Vautherot JF; Coursaget P
Arch Virol; 2006 Aug; 151(8):1511-23. PubMed ID: 16508703
[TBL] [Abstract][Full Text] [Related]
29. High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.
Guan J; Bywaters SM; Brendle SA; Ashley RE; Makhov AM; Conway JF; Christensen ND; Hafenstein S
Viruses; 2017 Dec; 9(12):. PubMed ID: 29211035
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
Day PM; Gambhira R; Roden RB; Lowy DR; Schiller JT
J Virol; 2008 May; 82(9):4638-46. PubMed ID: 18305047
[TBL] [Abstract][Full Text] [Related]
31. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
32. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
33. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
[TBL] [Abstract][Full Text] [Related]
34. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.
Zhang C; Huang X; Chen S; Li Y; Li Y; Wang X; Tang J; Xia L; Lin Z; Luo W; Li T; Li S; Zhang J; Xia N; Zhao Q
Vaccine; 2018 Oct; 36(45):6761-6771. PubMed ID: 30287156
[TBL] [Abstract][Full Text] [Related]
35. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
[TBL] [Abstract][Full Text] [Related]
37. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
[TBL] [Abstract][Full Text] [Related]
38. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
39. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
[TBL] [Abstract][Full Text] [Related]
40. Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.
Bywaters SM; Brendle SA; Biryukov J; Wang JW; Walston J; Milici J; Roden RB; Meyers C; Christensen ND
Virology; 2018 Nov; 524():106-113. PubMed ID: 30170240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]